Praxis Partners with Remagine Labs to Develop Transdermal Patch for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines has partnered with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide, an investigational T-type calcium channel inhibitor under FDA review for the treatment of essential tremor (ET). The collaboration combines Praxis’ late-stage CNS therapy with Remagine’s electronically controlled transdermal drug delivery platform, with the goal of expanding treatment options and extending the long-term value of the ulixacaltamide franchise.

The agreement includes a research collaboration and license to adapt Remagine’s proprietary active transdermal technology for multi-day delivery of ulixacaltamide. Praxis has also made an equity investment in Remagine Labs, reinforcing the companies’ commitment to accelerate development of the drug-device combination.

Ulixacaltamide is currently the most advanced investigational therapy specifically developed for essential tremor. The U.S. Food and Drug Administration accepted its New Drug Application (NDA) in April 2026 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027. The therapy received Breakthrough Therapy Designation in December 2025 based on positive findings from the Essential3 Phase 3 clinical program.

Expanding delivery options for essential tremor

Essential tremor is one of the most common movement disorders, affecting an estimated seven million people in the United States. Despite its prevalence, treatment options remain limited, and no medicine has been specifically developed and approved for the condition. Many patients continue to experience inadequate symptom control or difficulty tolerating existing therapies.

Ulixacaltamide selectively inhibits T-type calcium channels, a mechanism intended to reduce abnormal neuronal activity associated with tremor. While the lead program focuses on oral administration, the new collaboration explores an electronically controlled transdermal patch that could provide sustained drug delivery over multiple days.

Remagine’s platform uses iontophoresis, a technology that applies a controlled electrical current to actively transport drug molecules across the skin. If successful, the approach could offer an alternative administration route for patients who may benefit from non-oral therapy while potentially broadening the eligible patient population.

Strategic collaboration supports life-cycle expansion

Praxis said the transdermal program complements its ongoing NDA review rather than replacing the oral formulation. The company expects the additional delivery option to strengthen ulixacaltamide’s commercial positioning and create future life-cycle management opportunities.

President and Chief Executive Officer Marcio Souza said the collaboration reflects the company’s strategy to build beyond the initial oral product by developing differentiated delivery options that could increase patient access and support additional CNS programs in the future.

Remagine Labs Co-founder and Chief Executive Officer Pat Kelly said the partnership validates the company’s electronically controlled transdermal technology and provides an opportunity to evaluate its application in central nervous system therapeutics. He added that the collaboration could support the development of differentiated drug-device combination products.

Path Forward

Praxis will continue advancing the oral formulation of ulixacaltamide through FDA review while jointly developing the investigational transdermal patch with Remagine Labs. If approved, ulixacaltamide could become the first therapy specifically developed for essential tremor in decades, with the transdermal program representing a potential expansion of the franchise beyond its initial indication and delivery format.

Reference

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor – Praxis Precision Medicines, Inc.